Skip to content
value.today

InMed Pharmaceuticals Inc.

Formerly Meridex Network Corporation, Meridex Software Corporation, Cannabis Technologies Inc

Total raised
$14 M
2 rounds on record
Latest round
$12 M
Jul 2021
First round on record
Jan 2018
Today
Went public
See the company page

InMed Pharmaceuticals Inc. is listed today as Inmed Pharmaceuticals Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of InMed Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$6 MPrivate placement after listing$2 to $10 million

InMed Pharmaceuticals Inc.: Private sale, Nov 2022

Investors in this round

2 investors had bought by the notice of Dec 6, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$450,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Alexandra D.J. Mancini · Executive Officer
  • Eric A. Adams · Executive Officer, Director
  • Eric C. Hsu · Executive Officer
  • Michael D.J. Woudenberg · Executive Officer
  • Sarah A. Li · Executive Officer
  • Andrew J. Hull · Director
  • Bryan J. Baldasare · Director
  • Janet J. Grove · Director
  • Nicole J. Lemerond · Director
  • William J. Garner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition to the $450,000, the issuer paid to the sole placement agent in the offering, a management fee of $60,000, $20,000 for non-accountable expenses and $35,000 for fees and expenses of legal counsel and other out-of-pocket expenses.”
  • On the amounts: “Consists of (i) $6,000,010.50 received and (ii) approximately $166.82 to be received upon exercise of pre-funded warrants sold in the offering to purchase up to an aggregate of 1,668,185 common shares at an exercise price of $0.0001 per share.”

Signed by Eric A. Adams, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 6, 2022. Read the notice at the SEC.

equity, optionsSEC
Jun 2022$5 MPrivate placement after listing$2 to $10 million

InMed Pharmaceuticals Inc.: Private sale, Jun 2022

Investors in this round

1 investor had bought by the notice of Jun 8, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$375,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Alexandra D.J. Mancini · Executive Officer
  • Brenda A. Edwards · Executive Officer
  • Eric A. Adams · Executive Officer, Director
  • Eric C. Hsu · Executive Officer
  • Michael C. Woudenberg · Executive Officer
  • Adam J. Cutler · Director
  • Andrew J. Hull · Director
  • Bryan J. Baldasare · Director
  • Janet J. Grove · Director
  • William J. Garner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ROTH Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in all US states
  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states

Signed by Eric A. Adams, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 8, 2022. Read the notice at the SEC.

equity, optionsSEC
Oct 2021$4 MIssued in a merger or acquisition$2 to $10 million

InMed Pharmaceuticals Inc.: Private sale, Oct 2021

Investors in this round

54 investors had bought by the notice of Oct 28, 2021: 52 accredited, 2 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Alexandra D.J. Mancini · Executive Officer
  • Bruce S. Colwill · Executive Officer
  • Eric A. Adams · Executive Officer, Director
  • Eric C. Hsu · Executive Officer
  • Michael C. Woudenberg · Executive Officer
  • Adam A. Cutler · Director
  • Andrew A. Hull · Director
  • Catherine A. Sazdanoff · Director
  • William J. Garner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering made to prior stockholders of BayMedica, Inc., as part of the merger consideration. Total amount sold based on a per share price of $2.10.”
  • On a merger: “Offering made to prior stockholders of BayMedica, Inc., as part of the merger consideration.”

Signed by Bruce S. Colwill, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 28, 2021. Read the notice at the SEC.

equitySEC
Jul 2021$12 MNo. 2$10 to $50 million

InMed Pharmaceuticals Inc.: Raise no. 2, Jul 2021

Investors in this round

1 investor had bought by the notice of Jul 19, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$900,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Alexandra D.J. Mancini · Executive Officer
  • Bruce S. Colwill · Executive Officer
  • Eric A. Adams · Executive Officer, Director
  • Eric C. Hsu · Executive Officer
  • Michael C. Woudenberg · Executive Officer
  • Adam A. Cutler · Director
  • Andrew A. Hull · Director
  • Catherine A. Sazdanoff · Director
  • William J. Garner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states
  • ROTH Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in all US states

Signed by Eric A. Adams, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 19, 2021. Read the notice at the SEC.

equity, optionsSEC
Jan 2018$2 MNo. 1Under $2 million

InMed Pharmaceuticals Inc.: Raise no. 1, Jan 2018

Investors in this round

2 investors had bought by the notice of Jan 17, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Units, each comprised of one common share and one share purchase warrant exercisable at CAD$1.25 for 18 months
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$67,722
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Alexandra D.J. Mancini · Executive Officer
  • Eric A. Adams · Executive Officer, Director
  • Jeff J. Charpentier · Executive Officer
  • Sazzad J. Hossain · Executive Officer
  • Adam A. Cutler · Director
  • Andrew J. Hull · Director
  • Martin A. Bott · Director
  • William J. Garner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Canaccord Genuity Corp. · broker-dealer Canaccord Genuity Inc. (CRD 1020) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “US dollar amounts herein have been converted from Canadian dollars based on the 0.7979 Bank of Canada daily exchange rate in effect on 1-3-18. Total Remaining to be Sold represents the aggregate exercise price of all warrants sold in the offering.”
  • On the use of proceeds: “Proceeds from the offering may be used for general working capital purposes. Thus, proceeds may be used for payments to officers and directors in the ordinary course, but they are not specifically earmarked for such payments.”

Signed by Jeff Charpentier, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 17, 2018. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • InMed Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2022

That is all the official record says: InMed Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of InMed Pharmaceuticals Inc. are on record.

Investors#

No investor of InMed Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 2 investors.

Largest shareholders today

Institutions holding Inmed Pharmaceuticals Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by InMed Pharmaceuticals Inc.
NameRoleNamed in
Alexandra D.J. ManciniExecutive officerDec 2022
Eric A. AdamsExecutive officerDec 2022
Eric C. HsuExecutive officerDec 2022
Michael D.J. WoudenbergExecutive officerDec 2022
Sarah A. LiExecutive officerDec 2022
Brenda A. EdwardsExecutive officerJun 2022
Michael C. WoudenbergExecutive officerJun 2022
Bruce S. ColwillExecutive officerOct 2021
Jeff J. CharpentierExecutive officerJan 2018
Sazzad J. HossainExecutive officerJan 2018
Andrew J. HullDirectorDec 2022
Bryan J. BaldasareDirectorDec 2022
Eric A. AdamsDirectorDec 2022
Janet J. GroveDirectorDec 2022
Nicole J. LemerondDirectorDec 2022
William J. GarnerDirectorDec 2022
Adam J. CutlerDirectorJun 2022
Adam A. CutlerDirectorOct 2021
Andrew A. HullDirectorOct 2021
Catherine A. SazdanoffDirectorOct 2021
Martin A. BottDirectorJan 2018

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.